After 12–18 months of therapy for MASH, what specific NIT-based threshold (and which NITs) do you use to define ‘inadequate response’ that triggers adding a liver-directed agent (e.g., a thyroid hormone receptor-beta agonist) rather than continuing to observe—given day-to-day NIT variability and the risk of missing progression in true F2–F3 disease?